Skip to main content
Lyka Labs Ltd. logo

Lyka Labs Ltd. — Investor Relations & Filings

Ticker · LYKALABS ISIN · INE933A01014 LEI · 3358001RHQJBCTT1ER45 BSE.NS Manufacturing
Open in API
Filings indexed 1,205 across all filing types
Latest filing 2024-08-01 Regulatory Filings
Country IN India
Listing BSE.NS LYKALABS

About Lyka Labs Ltd.

https://www.lykalabs.com

Lyka Labs Ltd. specializes in the development, manufacture, and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company maintains a diverse product portfolio spanning multiple therapeutic categories, including anti-infectives, dermatologicals, cardiovascular agents, and pain management. A significant area of expertise for the organization is lyophilization technology, enabling the production of high-quality injectable formulations. The company operates advanced manufacturing facilities designed to meet international quality standards, supporting its operations in both domestic and global markets. Its core activities encompass the production of various dosage forms such as tablets, capsules, ointments, and sterile injectables, with a particular focus on specialized segments like cephalosporins and critical care medications.

Recent filings

Filing Released Lang Actions
Board Meeting — LYKA LABS LIMITED has informed the Exchange about Board Meeting to be held on 09-Aug-2024 to consider and approve the Quarterly Unaudited Financial results of the Company for the peri…
Regulatory Filings
2024-08-01 English
Board Meeting — Financial Results/Other business matters
Board/Management Information Classification · 95% confidence The document is a short notice dated 1st August 2024 from Lyka Labs Limited addressed to stock exchanges informing about a forthcoming Board Meeting scheduled for 9th August 2024. The purpose of the meeting is to consider and approve unaudited standalone and consolidated financial results for the quarter ended 30th June 2024. The document does not contain any financial data or results itself, only an announcement of the meeting where such results will be approved. The length is only 1809 characters, which is short and consistent with an announcement rather than a full report. Therefore, this document is an announcement of a Board Meeting related to financial results, which fits best under Board/Management Information (MANG) as it relates to board meeting notifications and management decisions. It is not a full Interim/Quarterly Report (IR) because it does not contain financial statements or substantive financial data, only a notice of the meeting to approve such results.
2024-08-01 English
LYKA LABS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/08/2024 ,inter alia, to consider and approve The Company submit the details of ....
Regulatory Filings Classification · 95% confidence The document is a letter dated 1st August 2024 from Lyka Labs Limited addressed to stock exchanges, informing about a scheduled Board Meeting on 9th August 2024. The purpose of the meeting is to consider and approve unaudited standalone and consolidated financial results for the quarter ended 30th June 2024. The document does not contain any financial data or results itself, but is an announcement of an upcoming board meeting where financial results will be approved. The document length is short (1809 characters) and it serves as a notification rather than a report. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement and notification to the stock exchanges about the board meeting and financial results approval date, rather than an Interim Report (IR) or Earnings Release (ER) which would contain actual financial data.
2024-08-01 English
Amalgamation/Merger
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It provides an update on the status of a Scheme of Amalgamation case filed before the National Company Law Tribunal (NCLT). The letter references previous communications and informs about the adjournment and next hearing date of the case. The document is short (1992 characters) and serves as an update or announcement rather than a detailed report or financial statement. It does not contain financial data, audit information, or detailed management discussion. It is an announcement related to regulatory compliance and corporate legal proceedings. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-07-23 English
The Company submitted the updation on the NCLT hearing of the Scheme of Amalgamation, as mentioned therein.
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges providing an update on the status of a Scheme of Amalgamation involving Lyka Labs Limited. It references regulatory compliance under SEBI Listing Obligations and Disclosure Requirements (Regulation 30), which pertains to disclosure of material events. The content is an update on a legal proceeding before the National Company Law Tribunal (NCLT) regarding the amalgamation case, including adjournment and next hearing date. The document is short (1992 characters) and serves as a regulatory announcement rather than a detailed report or financial statement. It does not contain financial data, audit information, or detailed management discussion. It is not a report publication announcement since it does not mention any report being published or attached. The document fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance update.
2024-07-23 English
Amalgamation/Merger
Regulatory Filings Classification · 95% confidence The document is a short regulatory update under SEBI Listing Obligations and Disclosure Regulations, 2015, regarding the status of a Scheme of Amalgamation hearing before the National Company Law Tribunal (NCLT). It references a previous intimation and informs about the postponement of the hearing date. The document is only 1966 characters long and does not contain any financial statements, detailed financial data, or comprehensive report content. It is an announcement/update about a legal proceeding related to corporate restructuring, not a full legal proceedings report or merger filing. Given the nature and length, it fits best as a Regulatory Filing (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-07-19 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.